Title	Perspectives in Antiinfective Therapy [electronic resource] / edited by George Gee Jackson, H. D. Schlumberger, H.-J. Zeiler
Imprint	Berlin, Heidelberg : Springer Berlin Heidelberg, 1989
Connect to	http://dx.doi.org/10.1007/978-3-642-46666-3
Descript	XVII, 478p. 101 illus. online resource

Pharmaceutical research has a long-standing tradition at Bayer since the establishยญ ment of a Pharmaceutical Department 25 years after the foundation of the Farbenยญ fabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888, one of the first antipyretic drugs, phenacetin, was synthesized. A milestone was marked by the discovery and launch of Aspirin TM in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (GermaninTM) in the treatment of sleeping sickness led not only to the worldwide recognition of Bayer as a pharmaceutical company but also to intense research into antiinfective therapy. The antimalarial drugs Atebrin TM, Plasmochin TM and Resochin TM were the first of a whole series of significant contribuยญ tions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy were heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, Prontosilโ{132}ข, opened the new era of therapeutic control of bacterial infections. In 1939, Domagk received the Nobel Prize for Medicine for this breakthrough. A further breakthrough in the chemotherapy of the scourge of tuberยญ culosis was achieved in 1946 by Domagk and his colleagues Behnisch, Mietzsch and Schmidt with the development of Conteben TM, followed shortly afterwards by the discovery of isoniazid (Neoteben TM) by Domagk, Offe and Siefken

The Challenge of Perspective -- History and Philosophy of Bayer Pharmaceutical Research -- On Bacteriological Research -- Background to Robert Kochโ{128}{153}s Lecture at the International Congress in Berlin, 1890 -- Classical Mechanisms of Antibacterial Drags -- Multiple Penicillin Binding Protein Profiles in Penicillin Resistant Pneumococi: Evidence for the Clonal Nature of Resistance Among Clinical Isolates -- Antibiotic Uptake into Gram-Negative Bacteria -- Inhibition of Protein Biosynthesis by Antibiotics -- Inhibition of DNA Gyrase: Bacterial Sensitivity and Clinical Resistance to 4-Quinolones -- Mechanisms of Nonbacterial Antiinfective Drags -- Mechanisms of Antiretroviral Compounds in Inhibition of Viral and Cellular DNA Polymerases -- Effects of Drugs on Lipids and Membrane Integrity of Fungi -- Membrane Changes Induced by Praziquantel -- Mechanisms of Action of Antimalarial Drugs -- Pathogenic Microbial Mechanisms Susceptible to Drug Application -- Bacterial Adherence in Pathogenicity -- Haemophilus influencae Gene Expression and Bacterial Invasion -- Coordinate Regulation of Bacterial Virulence Genes -- Microbial Drug Resistance -- Transposon Transfer of Drug Resistance -- Bacterial Proteins Involved in Antimicrobial Drug Resistance -- Persistent Herpes Simplex Virus Infection and Mechanisms of Virus Drug Resistance -- Pharmacology and Drug Delivery -- Antiviral Therapy with Small Particle Aerosols -- Liposomes and Lipid Structures as Carriers of Amphotericin B -- Targeted Liposomes Bearing Sendai for Influenza Envelope Glycoproteins as a Potential Carrier for Protein Molecules and Genes -- Host Determinants in Antiinfective Chemotherapy -- Cell-Mediated Immunity, Immunodeficiency and Microbial Infections -- Neutropenia: Antibiotic Combinations for Empiric Therapy -- Infection Prevention by Modulation of Host Flora -- Enhancement of Resistance in the Immunocompromised Host by Control of Fungal Growth -- Nonvaccine Immunoalteration of the Host -- Passive Immunotherapy of Infectious Diseases: Lessons from the Past, Directions for the Future -- T-Cell Mediated Immunopathology in Viral Infections -- New Diseases and Disease Epidemiology -- Adherence and Proliferation of Bacteria on Artificial Surfaces -- Current Knowledge of Chlamydia TWAR, and Important Cause of Pneumonia and Other Acute Respiratory Diseases -- Current Status of Antiviral Chemotherapy for Genital Herpes Simplex Infection: Its Impact on Disease Control -- Induction and Maintenance Therapy for Opportunistic Infections in Patients with AIDS -- New Technology and Drug Design -- Nucleic Acid Hybridization: A Rapid Method for the Diagnosis of Infectious Diseases -- New Technology and Immunospecific Reactions in Helminthic Diseases -- Molecular Targets of Chemotherapeutic Agents Against the Human Immunodeficiency Virus -- Modern Strategies in the Design of Antimicrobial Agents -- Future Development and Use of Antiinfective Chemotherapy -- The Future Challenge of Infectious Disease -- Barriers to Effective Antiinfective Therapy. The Perspective of a Clinical Pharmacologist -- Optimal Use of Antimicrobial Agents -- Views of Future Antiinfective Therapy